Category Row Item Charity: What we do
Services offered
-Areas where the Demoucelle Parkinson Charity can provide consulting support :
- Business advice: provide business advice to start-ups
- Presentation quality: enhance chances of start-ups with good ideas to get funding
- Sense of urgency: motivate clinicians to speed up finding patients for clinical trials
- Positive culture: help develop culture in the organisation where everybody can give personal best (even in difficult circumstances)
- Teamness & alignment: get all noses in the same direction
- Inspiring leadership: teach managers how develop clear vision and how to enroll others
- Sustainable peak performance: help team members reach always higher ambitions, without them getting in overdrive
Pro-bono consulting
-The Demoucelle Parkinson Charity was founded by 2 former top-consultants and business leaders, Patrick & Anne-Marie Demoucelle. Given their background, they decided on the unconventional strategy to offer their business skills as a leverage to cure-oriented projects and prominent organizations in the Parkinson field.
Steering funded projects
-We support exciting and promising disease-modifying projects in Europe in collaboration with the Michael J. Fox Foundation.
- InterMed
(DPC invested in 2012).
Objective: identify the potential of a molecule to be neuroprotective and become a disease-modifying therapeutic. Read more
- Affiris: The Affitope Parkinson Vaccine
(DPC invested in 2012)
Objective: perform first phase clinical trial and check impact of the vaccine on α-synuclein, a brain component that plays a central role in the pathogenesis of Parkinson’s Disease. Watch our video Read more - Exenatide
(DPC invested in 2013)
Objective: perform a randomized, double-blind, placebo-controlled, proof-of-concept trial to confirm whether the preliminary findings of beneficial effects seen in both motor and non-motor PD symptoms can be replicated. Read more
- nLife Thera
(DPC invested in 2015)
Objective: characterize the dose and efficacy of a new molecule in a model of Parkinson’s disease vs a healthy model. Watch our video Read more.
- AC Immune
(DPC invested in 2015 & 2018)
Objective: develop a brain imaging agent for alpha-synuclein, a key protein involved in PD pathology. Watch our video Read more
- Khondrion
(DPC invested in 2016)
Objective: test the effectiveness of a molecule against the mitochondrial dysfunction, often noted in Parkinson’s Disease. Read more
- Nilotinib
(DPC invested in 2016 & 2017)
Objective: check whether the effectiveness of the medicine, shown in open trials, is confirmed in a large double-blind, placebo-controlled trial. Read more. Further info.
- ADx Neurosciences
(DPC invested in 2017)
Objective: develop guidelines for clinical trials.
- ATP10B
(DPC invested in 2019)
Objective: better understand the mutation of this gene, and its potential impact on Parkinson’s disease. Read more
- ATP13A2
(DPC invested in 2020)
Objective: To develop a pre-clinical drug candidate Read more
- University of Texas
(DPC invested in 2021)
Objective: To carry out human trials to test whether multiple intravenous infusions of mesenchymal stem cells will significantly slow the progression of Parkinson’s disease. Read more
- Modag Anle 138b
(DPC invested in 2022)
Objective: Further in-patient testing of a drug targeting the buildup of protein alpha-synuclein in the brain. Read more
- Libra TRPML1
(DPC invested in 2023)
Objective: improve the ability of the brain cells to deal with old and damaged molecules by activating TRPML1.
Read more
- Samsara
(DPC invested in 2023)
Objective: test the ability of small molecules to reduce the accumulation of alpha-synuclein in the brains of mice. Read more
- VesperBio
(DPC invested in 2023 & 2024)
Objective: test the efficacy of Vesper compounds in three in vivo models. Read more
- Lys Therapeutics
(DPC invested in 2023 & 2024)
Objective: better understand the role of T cell infiltration and provide strong proof of concept data for Glunomab immunotherapy use as a treatment for Parkinson’s. Read more
- Coave Therapeutics
(DPC invested in 2023 & 2024)
Objective: Preclinical proof of concept of TFEB in Parkinson disease. Read more. (Last update autumn 2023)
- Galvani Bioelectronics
(DPC invested in 2023 & 2024)
Objective: test the effect of splenic nerve stimulation to reduce inflammation-driven Parkinson’s progression and LRRK2 mutation-driven Parkinson’s risk. Read more
-
TrkB – Ossianix
(DPC invested in 2025)
Objective: To carry out preclinical tests to establish whether the TrKB antibody is able to reach the brain, protect neurons, and increase dopamine production.
Read more -
ACT-02 – Accure
(DPC invested in 2025)
Objective: To finalise critical safety and pharmacology studies needed to submit an Investigational New Drug (IND) application for oral drug ACT-O2 targeting the PREP protein.
Read more
The Demoucelle Parkinson Charity receives frequent project updates and participates in project check-in calls and in-person project assessments organized by staff of the Michael J. Fox Foundation.
Please click here to read updates on our projects (December 2022).
SUPPORTING DISEASE-MODIFYING RESEARCH PROJECTS
-Currently, all available Parkinson’s disease treatments are focused on alleviating symptoms i.e. they help to (temporarily) reduce/manage the symptoms of the disease. In order to achieve a real breakthrough, the Demoucelle Parkinson Charity supports research that aims to modify the disease i.e. slow down, halt or even reverse the progression of the disease.
The Demoucelle Parkinson Charity partners with the Michael J. Fox Foundation for Parkinson’s Research and applies the following project selection criteria:
— Disease-modifying therapeutics (i.e. focused on finding a cure)
— In pre-clinical development or beyond (i.e. late-stage research)
— In Belgium and elsewhere in Europe
So far, the Demoucelle Parkinson Charity has invested in 18 promising projects. For more information, see below.
What we do with the funds raised
-Projects are chosen in collaboration with the experts of the Michael J. Fox Foundation – thé foundation worldwide active in Parkinson’s research.
So far, the Demoucelle Parkinson Charity has provided funding to 12 projects – 10 in Europe, 2 in the US.
Click here to learn more
How we raise funds
-It’s through people like you that we raise the funds allowing us to support the most promising projects.
We seek the support of as many people as possible to spread the word and raise funds for our charity.
There’s many ways you can help: